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Lack of association of statin use with Vitamin D
levels in a hospital based population of
type 2 diabetes mellitus patients
Khalida Iqbal1, Najmul Islam2, Iqbal Azam3,
Naseema Mehboobali5, Mohammad Perwaiz Iqbal6
ABSTRACT
Objective: To investigate the relationship of statins (drug given to reduce serum levels of LDL-cholesterol)
on vitamin D levels of Pakistani type 2 diabetes mellitus (DM) patients in a hospital in Karachi.
Methods: In a cross-sectional survey, 312 consecutive patients with type 2 DM (219 males and 93 females,
age 22-70 years) were recruited with informed consent. A questionnaire was administered to find out
whether they were statin users or non-users. Serum was analyzed for concentrations of 25(OH) vitamin D
[25(OH)D] and other related biomarkers such as serum cholesterol, triglycerides, HDL-cholesterol, LDLcholesterol, phosphate and calcium using kit methods. Multiple Linear Regression was used to evaluate
association of statin use with serum levels of vitamin D while adjusting for related covariates including
duration of statin use, duration of type 2 DM and smoking.
Results: Mean concentrations of serum cholesterol, and LDL-cholesterol were lower among statin users
compared to statin non-users (P < 0.01), while HDL-cholesterol levels were higher (P<0.01). No relationship
was observed between statin use and serum levels of vitamin D (P=0.768), when adjusted for age, gender,
BMI, duration of type 2 DM, smoking, serum cholesterol and LDL-cholesterol. The adjusted regression
coefficient (β) and standard error [SE(β)] for statin use duration were 0.012 (0.042), when serum levels of
vitamin D was taken as an outcome.
Conclusion: Lack of association was found between statin use and vitamin D levels in a hospital-based
population of Pakistani patients with type 2 DM.
KEY WORDS: Diabetes mellitus, Pakistani population, Statins, Vitamin D levels.
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INTRODUCTION
Statins are a group of cholesterol lowering drugs
which inhibit HMG-CoA reductase, a key enzyme
in the cholesterol biosynthesis. They have a wellestablished role in decreasing serum concentration
of low density lipoprotein (LDL) cholesterol, thereby
reducing the risk of atherosclerotic cardiovascular
disease (CVD).1 A Cochrane review in 2013 has
indicated a role of statins in the primary prevention
of CVD in people with no history of this disease.2
An association between CVD risk and vitamin D
deficiency has also been reported in a number of
studies.3,4
The deficiency of vitamin D is a global health
problem and its prevalence is very high in South
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Asian populations including Pakistan.5,6 A few
studies have shown that statins significantly
increase serum levels of vitamin D metabolite,
25-hydroxyvitamin D (25(OH)D).7,8 However, a
recent systematic review and meta-analysis of
7 studies including 5 randomized clinical trials
showed no significant effect of statin treatment
on plasma levels of vitamin D.9 It has even been
suggested that statin therapy may impair vitamin D
status, thereby leading to increased risk of CVD.10,11
More recently, a meta-analysis on the effect of statins
on vitamin D levels was inconclusive and reported
“conflicting directions of effects from interventional
and observation studies”.12
Since no studies have been carried out on South
Asian population on the relationship of statin use
and vitamin D status, we embarked on investigating
this relationship in Pakistani diabetic patients who
are often put on statins to reduce CVD risk while
managing the blood glucose levels. Therefore, the
objective of this study was to find out if there is any
association between statin use and vitamin D levels
in a hospital based population of Pakistani patients
with type 2 diabetes mellitus (DM).
METHODS
In a cross-sectional survey for the assessment of
the role of statins on vitamin D levels in type 2 DM

patients, 312 consecutive patients (age 22-70 years;
219 males and 93 females) were recruited from the
Endocrinology Clinics of the Aga Khan University
Hospital (AKUH) with informed consent. These
patients had confirmed diagnosis of type 2 DM
on the basis of clinical history and fasting serum
glucose > 126 mg/dl as per guidelines of the
International Diabetes Federation. According to the
inclusion criteria, they had not been taking vitamin
D supplements for the last 6 months and were not
suffering from any of the chronic diseases such as
tuberculosis, liver disease, uremia or cancer and
were not pregnant. Majority of the recruited patients
(65%) were newly diagnosed diabetes patients with
duration of diabetes less than 6 months. Seventeen
percent of patients had duration of the disease for
more than 60 months. All the patients were on oral
hypoglycemic drugs. Those on statins had been on
daily dosages 5 mg (13%), 10 mg (55%) and 20 mg
(32%). The study had been approved by the Ethics
Review Committee of the Aga Khan University.
A brief questionnaire was used for demographic
information and to find out whether they were
using statins or not. Ten ml fasting (at least 4
hours) blood was collected and serum/plasma
was analyzed for 25(OH) vitamin D [25(OH)D],
cholesterol, LDL-cholesterol, HDL-cholesterol,
triglycerides, phosphate and calcium using kit

Table-I: Demographic and clinical characteristics of type 2 DM patients with respect to statin use and non-use.
Statin nonusers
(n=160)

Variable

Mean±SD

n(%)

Statin users
(n=152)

Mean±SD

P*

n(%)

Gender
Males (n=219)
Females (n=93)

108(67.5)
52(32.5)

-

111(73)
41(27)

-

0.29

Smoker (current)
No
Yes

128(80)
32(20)

-

122(80.3)
30(19.7)

-

0.95

Duration of DM (months)

-

35.8±46.8

-

63.9±70.3

<0.01

Age (yr)

-

45.6±10.5

-

50.8±8.7

<.01

BMI (kg/m )

-

29.8±5.5

-

29.9±5.2

0.22

Serum cholesterol (mg/dl)

-

162±48

-

127±46

<0.01

Triglyceride (mg/dl)

-

160±86

-

144±72

0.08

HDL-cholesterol (mg/dl)

-

25.03±7.80

-

29.29±8.91

<0.01

LDL-cholesterol (mg/dl)

-

90±36

-

63±39

<0.01

2

Phosphate (mg/dl)

-

3.6±0.70

-

3.75±0.74

0.27

Calcium (mg/dl)

-

9.93±1.8

-

9.71±1.93

0.30

25(OH)D (ng/ml)

-

18.62±11.63

-

20.3±11.6

0.23

*P was obtained by comparing mean values of two groups (statin users and non-users) using Independent samples t
test, while percentages in the two groups (statin users and non-users) were compared using chi square.
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methods (Roche Diagnostics Indianapolis, IN).
For quality assurance, standard controls with high
and low concentrations of biomarkers were run
along with the test samples.
Statistical analysis: Statistical analyses were
carried out using Statistical Package for Social
Sciences® (SPSS) software version 19 for Windows®
(Apache Software Foundation, USA). Mean values
of continuous variables such as age, BMI, serum
levels of cholesterol, triglyceride, HDL-cholesterol,
LDL-cholesterol, phosphate, calcium, 25(OH)D,
duration of diabetes and duration of statin use were
expressed as mean±SD, while categorical variables
such as gender and smoking status were expressed
as n(%). Mean values of variables in two groups
(statin users and statin non-users) were compared
using Independent sample t test. Multiple linear
regression was used to observe the relationship
between vitamin D levels and statin use, which was
also adjusted for demographic and health related
covariates.
RESULTS
As shown in Table I, mean age and duration
of diabetes in the statin non-users group were

significantly lower compared to the statin users
group (P < 0.01). Similarly, mean concentrations
of serum cholesterol and LDL cholesterol were
significantly lower in the statin users group
compared to the non-users group (P < 0. 01).
However, HDL-cholesterol levels were significantly
higher in the statin users group (P < 0.01). No
significant difference was found when the mean
values of 25(OH)D between statin-users and statin
non-users were compared using Independent
sample t test (P = 0.23). No significant differences
with respect to other variables were found between
the two groups.
Regarding mean duration of statin use and
dosages of statins, out of 152 statin users, the data
of 118 were available for regression analysis. Mean
duration of statin treatment among the statin users
group was 17.99±21.42 months, while the mean
dosage of statins in this group was 12.7±5.3 mg.
The effect of different factors, particularly duration
of statin use is shown in Table II. Gender, age, BMI,
duration of DM, levels of serum cholesterol, HDLcholesterol and calcium were found to be significant
at the univariate level.

Table-II: Effect of statin use on the serum levels of vitamin D using multiple linear regression.
Variable

Crude
β[SE(β)]**

P

Adjusted*
β[SE(β)]**

P

Statin use duration (months)

0.07(0.039)

0.076

0.012(0.042)

0.768

Age (yr)

0.227(0.067)

0.001

0.117(0.071)

0.099

0.031

3.496(1.47)

0.018
-

Gender
Male (Ref.)***
Female

3.176(1.47)

-

BMI (kg/m )

-0.338(0.133)

0.005

-0.294(0.132)

0.027

Type 2 DM duration (months)

0.041(0.011)

<0.001

0.035(0.013)

0.006

Current Smoking
No (Ref.)***
Yes

-1.495(1.728)

0.388
-

0.974(1.765)

0.582
-

Cholesterol (mg/dl)

-0.28(0.014)

0.043

-0.057(0.019)

0.003

LDL-C (mg/dl)

-0.011(0.017)

0.500

0.062(0.024)

0.01

HDL-C (mg/dl)

0.16(0.076)

0.035

-

-

Triglyceride (mg/dl)

0.006(0.008)

0.468

-

-

Phosphate (mg/dl)

-0.455(0.913)

0.618

-

-

Calcium (mg/dl)

-0.714(0.353)

0.044

-

-

-

-

22.915(5.740)

<0.001

2

Constant

*Model was adjusted for age, gender, BMI, duration of type 2 diabetes mellitus, current smoking, serum cholesterol
and LDL-cholesterol with coefficient of determination (R2)= 0.135.
** β[SE(β)] refers to regression co-efficient with its standard error.
***Ref. indicates the reference group category in regression.
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At multivariable level, when the relationship
between duration of statin use and serum level of
vitamin D was adjusted for other factors, which
were either biologically important or significant
at the univariate level, the variables like gender,
BMI, duration of type 2 diabetes, serum levels of
cholesterol and LDL-cholesterol were found to be
significantly associated.
Current smoking was kept in the model because
of its biological importance.6 Regarding the duration
of statin use, one month increase in statin use was
found to be responsible for an average increase in
vitamin D level by 0.012 ng/ml when adjusted for
age, gender, BMI, duration of type 2 DM, current
smoking, serum cholesterol and LDL-cholesterol.
The value of coefficient of determinations (R2)
of 0.135 indicates that 13.5% variation in serum
level of vitamin D is explained by the investigated
covariates.
DISCUSSION
There are numerous reports about high prevalence of hypovitominosis D in South Asian general
population as well as patients with type 2 DM.13-15
Since diabetic patients have an additional risk of
developing CVD, they are often prescribed statins
to control their LDL cholesterol along with usual
management of their serum glucose level. However, long-term use of statins may produce hepatotoxicity. Since cholesterol metabolism and vitamin D
both share a common metabolic pathway, it is possible that prolonged use of statins would not only inhibit cholesterol biosynthesis but also reduce levels
of 7-dehydrocholesterol, a precursor molecule for
vitamin D3, thereby leading to low concentration of
vitamin D in the body.16 This would render such patients vulnerable to risks associated with vitamin D
deficiency. However, in the present study we found
no difference in serum levels of vitamin D in statin
users and non-users in type 2 DM patients. Similar
findings have been reported by Ertugrul et al, who
have shown no significant effect of pravastatin and
fluvastatin on serum levels of 25(OH)D.17 In a randomized controlled trial on healthy postmenopausal
women, simvastatin was found to have no effect on
vitamin D status even after 52 weeks of treatment.18
Similar results have been found by Mazidi et al on
an Iranian population of patients with dyslipidemia.19 On the contrary, Sathyapalan et al have reported increased concentration of 25(OH)D following
therapy with atorvastatin in type 2 DM patients in
UK.20 Similarly, 4 studies (two carried out in Turkey, one in Spain and another one in Germany) have
Pak J Med Sci
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also shown increased serum levels of 25(OH)D following treatment with rosuvastatin and atorvastatin.8,17,21,22 Most of these studies reporting increased
levels of 25(OH)D following statin treatment had
small sample sizes which could lead to overestimation of therapy effect, and therefore, it was difficult
to derive any substantive conclusion. Perhaps, this
could be the reason that most recent studies on this
pleotropic effect of statins have failed to show any
significant increase in vitamin D levels.19,23 A recent
meta-analysis of data from seven studies failed to
show any significant effect of statins treatment on
plasma concentrations of vitamin D.9 All these reports lend support to our current results indicating
lack of association between statin use and serum
levels of vitamin D in type 2 DM patients. The multiple linear regression model to investigate this relationship while adjusting for other related factors
mentioned above is a strength of this study.
Our results must be seen in the context of certain
limitations. Our collection of blood samples was
across the whole year and the samples could not be
divided into those collected during winter, spring or
summer. Furthermore, no dietary information was
obtained. However, in spite of these limitations, we
have been able to report lack of association between
statin use and vitamin D levels in a hospital-based
population of type 2 DM patients using a reasonably
large sample size.
In order to obtain conclusive evidence regarding
the relationship of statin use with vitamin D status in
South Asian population, prospective, randomized,
placebo controlled and double blinded multicentric
clinical trials with large sample size would be
required.
CONCLUSION
There is no association between statin use and
levels of vitamin D in a hospital-based Pakistani
population of type 2 DM patients.
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